Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Status:
Terminated
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases
of the white blood cells and are typically treated the same way. Recent research shows that a
key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase.
Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death of
CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some
effect on CLL cells. The purpose of this study is to see of the study drug dasatinib, in
combination with fludarabine and rituximab, is safe and effective to use for people with
relapsed or refractory CLL/SLL.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Bristol-Myers Squibb Dana-Farber Cancer Institute